About the Study

Do you continue to experience depressive episodes, despite having tried more than one anti-depressant medication?

This study is designed to investigate the efficacy of COMP360 (25 mg compared to 1mg), administered with psychological support in improving symptoms of depression.
This study is sponsored by Compass Pathways.

Length of Study: Up to 62 weeks in total, including a 3 to 10 week screening period

• Part A: Screening period, dosing period, plus a 9-week follow up from initial dosing day (11 on-site visits)
• Part B: A further 17-week follow up (26 weeks from initial dosing day)
• Part C: A further 26-week follow up (52 weeks from initial dosing day)

Eligibility 

You may be eligible to participate in this study if you:

• are 18 years of age or older
• have been diagnosed with Major Depressive Disorder
• have Treatment-Resistant Depression (failure to respond to 2, 3, or 4 different pharmacological treatments for MDD)
• are willing to discontinue all prohibited medications at time of screening

If chosen for this study, you will be compensated for every study visit that you complete, and we can provide transportation if needed.

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.